Brief: ADC Therapeutics Doses First Patient In Phase 1 Clinical Trial Of ADCT-901 In Advanced Solid Tumors
27/09/2021 12:50
Sept 27 (Reuters) - ADC Therapeutics SA ADCT.N :
* ADC THERAPEUTICS DOSES FIRST PATIENT IN PHASE 1 CLINICAL
TRIAL
OF ADCT-901 IN ADVANCED SOLID TUMORS
Source text for Eikon: ID:nBw5TZGjFa
Further company coverage: ADCT.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ADC Therapeutics SA
See all newsADC Therapeutics plunges after patient deaths in blood cancer drug trial
ADC Therapeutics falls on higher rates of serious side-effects in cancer trial
Switzerland's ADC Therapeutics beats Q1 revenue estimates
Switzerland's ADC Therapeutics posts smaller‑than‑expected Q4 net loss on lower R&D spend
Brief: ADC Therapeutics Q4 Income From Operations USD -17.919 Million Vs. IBES Estimate USD -30.1 Million